Market Research Logo

OpportunityAnalyzer:Uveitis - Opportunity Analysis and Forecasts to 2026

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Significant Growth Is Expected in the Uveitis Market from 2016 to 2026
2.2 R&D and Corporate Strategies Within the Uveitis Market
2.3 A Long-Acting Treatment That Permanently Controls Inflammation, With a Good Short- and Long-Term Safety Profile, Remains Elusive
2.4 Market Opportunities for New Entrants
2.5 Late-Stage Pipeline Drugs Entering the Uveitis Market Will Be a Key Driver of Growth
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.2.1 Uveitis and Systemic Diseases
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Uveitis (2016-2026)
5.5.1 Diagnosed Incident Cases of Uveitis
5.5.2 Diagnosed Prevalent Cases of Uveitis
5.5.3 Age-Specific Diagnosed Prevalent Cases of Uveitis
5.5.4 Sex-Specific Diagnosed Prevalent Cases of Uveitis
5.5.5 Diagnosed Prevalent Cases by Anatomical Site of Inflammation
5.5.6 Diagnosed Prevalent Cases by Etiology
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis and Treatment
6.2.1 Diagnosis
6.2.2 Treatment Guidelines and Leading Prescribed Drugs
6.3 Clinical Practice
6.4 Humira (Adalimumab)
6.4.1 Overview
6.4.2 Efficacy
6.4.3 Safety
6.4.4 SWOT Analysis
6.5 Retisert (Flucinolone Acetonide)
6.5.1 Overview
6.5.2 Efficacy
6.5.3 Safety
6.5.4 SWOT Analysis
6.6 Ozurdex (Dexamethasone Acetate)
6.6.1 Overview
6.6.2 Efficacy
6.6.3 Safety
6.6.4 SWOT Analysis
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Therapies That Maintain Vision and Control Inflammation
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Therapies With Improved Safety Profiles
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Long-Acting and More Efficient Treatment
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Increased Physician Education and Improved Treatment Guidelines
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Development of Biomarkers and Different Diagnostic Tests for Various Uveitic Types
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
8 R&D Strategies
8.1 Overview
8.1.1 Uveitis as an Add-On Indication
8.1.2 Uveitis as a First Indication for a New Drug
8.1.3 Development of Ophthalmic Routes of Administration
8.1.4 Development of Novel Non-steroid Therapies
8.2 Clinical Trials Design
8.2.1 Lack of High-Quality Outcome Measures
8.2.2 Lack of Consensus on Outcome Measures
8.2.3 Corticosteroid-Sparing Therapy
9 Pipeline Assessment
9.1 Overview
9.2 Opsiria/DE-109 (Sirolimus)
9.2.1 Overview
9.2.2 Efficacy
9.2.3 Safety
9.2.4 SWOT Analysis
9.3 Durasert (Fluocinolone Acetonide)
9.3.1 Overview
9.3.2 Efficacy
9.3.3 Safety
9.3.4 SWOT Analysis
9.4 EGP-437 (Iontophoretic Dexamethasone Phospaste)
9.4.1 Overview
9.4.2 Efficacy
9.4.3 Safety
9.4.4 SWOT Analysis
9.5 CLS-TA (Triamcinolone Acetonide)
9.5.1 Overview
9.5.2 Efficacy
9.5.3 Safety
9.5.4 SWOT Analysis
9.6 ADX-102
9.6.1 Overview
9.6.2 Efficacy
9.6.3 Safety
9.6.4 SWOT Analysis
9.7 Biosimilars Assessment
9.8 Amjevita (Adalimumab Biosimilar)
9.8.1 Overview
9.8.2 SWOT Analysis
9.9 Imraldi (Adalimumab Biosimilar)
9.9.1 Overview
9.9.2 SWOT Analysis
9.10 Innovative Early Stage Approaches
9.10.1 Tesidolumab (LFG-316)
9.10.2 Orencia (Abatacept)
9.10.3 Dexamethasone Acetate (DexNP)
9.10.4 LME-636
9.10.5 Optiquel (B27-PD)
9.10.6 Filgotinib
9.11 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Prevalent Cases
11.3.3 Diagnosed Prevalent Cases by Anatomical Site of Inflammation
11.3.4 Diagnosed Cases and Drug-Treated Prevalence
11.3.5 Disease Severity
11.3.6 Drugs Included in Each Therapeutic Class
11.3.7 Launch and Patent Expiry Dates
11.3.8 General Pricing Assumptions
11.3.9 Individual Drug Assumptions
11.3.10 Generic Erosion
11.3.11 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
1.1 List of Tables
Table 1: Uveitis: Key Metrics in the 7MM
Table 2: SUN Working Group Anatomic Classification of Uveitis
Table 3: SUN Working Group Descriptors in Uveitis
Table 4: SUN Working Group Descriptors in Uveitis
Table 5: Systemic Diseases Associated with Uveitis
Table 6: Symptoms and Ocular Comorbidities of Uveitis
Table 7: Prognosis for Uveitis Patients
Table 8: Risk Factors, Comorbidities, and Associated Diseases for Uveitis
Table 9: 7MM, Diagnosed Incident Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016-2026
Table 10: 7MM, Diagnosed Prevalent Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016-2026
Table 11: Treatment Guidelines for Uveitis
Table 12: Most Prescribed Drugs for Uveitis by Class in the Global Markets, 2016
Table 13: Summary of Minor Therapeutic Classes, 2016
Table 14: Product Profile - Humira
Table 15: Humira SWOT Analysis, 2017
Table 16: Product Profile - Retisert
Table 17: Retisert SWOT Analysis, 2017
Table 18: Product Profile - Ozurdex
Table 19: Ozudex SWOT Analysis, 2017
Table 20: Comparison of Therapeutic Classes in Development for Non-infectious Uveitis, 2016-2026
Table 21: Product Profile - Opsiria
Table 22: Opsiria SWOT Analysis, 2017
Table 23: Product Profile - Durasert
Table 24: Durasert SWOT Analysis, 2017
Table 25: Product Profile - EGP-437
Table 26: EGP-437 SWOT Analysis, 2017
Table 27: Product Profile - CLS-TA
Table 28: CLS-TA SWOT Analysis, 2017
Table 29: Product Profile - ADX-102
Table 30: ADX-102 SWOT Analysis, 2017
Table 31: Adalimumab Biosimilars Being Developed in the 7MM/Globally
Table 32: Product Profile - Amjevita
Table 33: Amjevita SWOT Analysis, 2017
Table 34: Product Profile - Imraldi
Table 35: IMRALDI SWOT Analysis, 2017
Table 36: Innovative Early Stage Approaches for Non-infectious Uveitis, 2017
Table 37: Drugs in Development for Uveitis, 2017
Table 38: Clinical Benchmark of Key Pipeline Drugs - Anterior Uveitis
Table 39: Clinical Benchmark of Key Pipeline Drugs - Posterior Segment Uveitis
Table 40: Commercial Benchmark of Key Pipeline Drugs - Anterior Uveitis
Table 41: Commercial Benchmark of Key Pipeline Drugs - Posterior Segment Uveitis
Table 42: Key Events Impacting Sales for Uveitis, 2016-2026
Table 43: Uveitis Market - Global Drivers and Barriers, 2016-2026
Table 44: Key Historical and Projected Launch Dates for Uveitis
Table 45: Key Historical and Projected Patent Expiry Dates for Uveitis
Table 46: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Uveitis in 2016 and 2026
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, Pred Forte
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Local Therapy, Triesence
Figure 4: Anatomy of the Eye
Figure 5: Hypothetical Pathogenetic Model of Autoimmune Uveitis
Figure 6: Schematic Representation of T-helper Activation In Immune-Mediated Uveitis
Figure 7: Age-Standardized Diagnosed Prevalence of Uveitis, Men, All Ages, 2006-2026
Figure 8: Age-Standardized Diagnosed Prevalence of Uveitis, Women, All Ages, 2006-2026
Figure 9: Case Flow Map for Diagnosed Incident and Prevalent Cases of Uveitis
Figure 10: Sources Used for Diagnosed Incidence
Figure 11: Sources Used for Diagnosed Incident Cases by Anatomical Location of Inflammation
Figure 12: Sources Used for Diagnosed Incident Cases by Course of Disease
Figure 13: Sources Used for Diagnosed Incident Cases by Severity
Figure 14: Sources Used and Not Used for Diagnosed Prevalence
Figure 15: Sources Used for Diagnosed Prevalent Cases by Anatomical Location of Inflammation
Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases of Uveitis, Both Sexes, N, 2016
Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases of Uveitis, All Ages, N, 2016
Figure 18: 7MM, Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Both Sexes, All Ages, N, 2016
Figure 19: 7MM, Diagnosed Prevalent Cases of Uveitis by Etiology, Both Sexes, All Ages, N, 2016
Figure 20: Current Treatment of Uveitis
Figure 21: Unmet Need and Opportunity in Non-infectious Uveitis, 2017
Figure 22: Overview of the Development Pipeline in Non-infectious Uveitis
Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects Will Be Licensed for Non-infectious Uveitis in the 7MM During the Forecast Period
Figure 24: Competitive Assessment of the Late-Stage Pipeline Drugs for Anterior Segment Uveitis Benchmarked Against the SOC, Pred Forte
Figure 25: Competitive Assessment of the Late-Stage Pipeline Drugs for Posterior Segment Uveitis Benchmarked Against the local therapy, Triesence
Figure 26: Global (7MM) Sales Forecast by Country for Uveitis in 2016 and 2026
Figure 27: Global Sales Forecast by Class for Uveitis in 2016 and 2026
Figure 28: Sales Forecast by Class for Uveitis in the US in 2016 and 2026
Figure 29: Sales Forecast by Class for Uveitis in the 5EU in 2016 and 2026
Figure 30: Sales Forecast by Class for Uveitis in Japan in 2016 and 2026

OpportunityAnalyzer:Uveitis - Opportunity Analysis and Forecasts to 2026

Summary


Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatment of uveitis. Based on the diverse nature of uveitis , there is a high unmet need for varied therapy approaches. Significant efforts are being made to develop new treatments for uveitis, as current pharmacologic management, which is dominated by competitively priced corticosteroids and also immunosuppressive drugs, is notorious for the development of adverse side effects. 

GlobalData estimates the drug sales for uveitis in 2016 were approximately $416.5M across the 7MM covered in this report. Over the 10-year forecast period, the market is expected to grow to $897.1M at a CAGR of 8.0%.

The anticipated introduction of five new drugs will further drive the market by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules. These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth.

Scope

  • Overview of uveitis: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized uveitis market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including non-infectious mild and moderate anterior uveitis, non-infectious severe anterior uveitis, non-infectious intermediate, posterior and panuveitis), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the uveitis therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for uveitis therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
  • Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;